{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:43:28Z","timestamp":1770983008425,"version":"3.50.1"},"reference-count":120,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>In the incretin system, Glucagon-like peptide-1 (GLP-1) is a hormone that\ninhibits the release of glucagon and regulates glucose-dependent insulin secretion. In type 2 diabetes,\ncorrecting the impaired incretin system using GLP-1 agonist is a well-defined therapeutic\nstrategy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>This review article aims to discuss the mechanism of action, key regulatory events, clinical\ntrials for glycaemic control, and comparative analysis of semaglutide with the second-line antidiabetic\ndrugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Description:<\/jats:title>\n<jats:p>Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist with enhanced glycaemic\ncontrol in diabetes patients. In 2019, USFDA approved the first oral GLP-1 receptor agonist,\nsemaglutide, to be administered as a once-daily tablet. Further, recent studies highlight the ability\nof semaglutide to improve Glycemic control in obese patients with a reduction in body weight.\nStill, in clinical practice, in the type 2 DM treatment paradigm, the impact of oral semaglutide remains\nunidentified. This review article discusses the mechanism of action, pharmacodynamics, key\nregulatory events, and clinical trials regarding glycaemic control.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The review highlights the comparative analysis of semaglutide with the existing second-\nline drugs for the management of type 2 diabetes mellitus by stressing its benefits and adverse\nevents.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450122666210901125420","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T12:53:50Z","timestamp":1630500830000},"page":"311-327","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral Semaglutide in the Management of Type 2 DM: Clinical Status and\nComparative Analysis"],"prefix":"10.2174","volume":"23","author":[{"given":"Ilora","family":"Bandyopadhyay","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny","family":"Dave","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhavan","family":"Nampoothiri","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallikarjuna Rao","family":"Chamallamudi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka,India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2213-8587(13)70112-8","volume":"2","author":"Zimmet P.Z.","year":"2014","unstructured":"Zimmet P.Z.; Magliano D.J.; Herman W.H.; Shaw J.E.; Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014,2(1),56-64","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2337\/dc16-0273","volume":"39","author":"Zimmet P.Z.","year":"2016","unstructured":"Zimmet P.Z.; Alberti K.G.M.M.; Epidemiology of diabetes-status of a pandemic and issues around metabolic surgery. Diabetes Care 2016,39(6),878-883","journal-title":"Diabetes Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","volume":"383","author":"Tuomi T.","year":"2014","unstructured":"Tuomi T.; Santoro N.; Caprio S.; Cai M.; Weng J.; Groop L.; The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014,383(9922),1084-1094","journal-title":"Lancet"},{"key":"ref=4","first-page":"22","volume":"47","author":"Forouhi N.G.","year":"2019","unstructured":"Forouhi N.G.; Wareham N.J.; Epidemiology of diabetes. Medicine (United Kingdom) 2019,47,22-27","journal-title":"Medicine (United Kingdom)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.mpmed.2014.09.007","volume":"42","author":"Forouhi N.G.","year":"2014","unstructured":"Forouhi N.G.; Wareham N.J.; Epidemiology of diabetes. Medicine (Abingdon) 2014,42,698-702","journal-title":"Medicine (Abingdon)"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"Wild S.","year":"2004","unstructured":"Wild S.; Roglic G.; Green A.; Sicree R.; King H.; Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004,27(5),1047-53","journal-title":"Diabetes Care"},{"key":"ref=7","first-page":"16","volume":"4","author":"Meuleneire F.","year":"2008","unstructured":"Meuleneire F.; Management of diabetic foot ulcers using dressings with safetac: A review of case studie. Wounds 2008,4(4),16-30","journal-title":"Wounds"},{"key":"ref=8","first-page":"S8","volume":"38","year":"2015","unstructured":"American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2015,38,S8-S16","journal-title":"Diabetes Care"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"E550","DOI":"10.1152\/ajpendo.00326.2004","volume":"290","author":"Theodorakis M.J.","year":"2006","unstructured":"Theodorakis M.J.; Carlson O.; Michopoulos S.; Doyle M.E.; Juhaszova M.; Petraki K.; Egan J.M.; Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006,290(3),E550-E559","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/dia.2019.0185","volume":"22","author":"Bucheit J.D.","year":"2020","unstructured":"Bucheit J.D.; Pamulapati L.G.; Carter N.; Malloy K.; Dixon D.L.; Sisson E.M.; Oral semaglutide: A review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther 2020,22(1),10-18","journal-title":"Diabetes Technol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"Kapitza C.","year":"2015","unstructured":"Kapitza C.; Nosek L.; Jensen L.; Hartvig H.; Jensen C.B.; Flint A.; Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol 2015,55(5),497-504","journal-title":"J Clin Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.2337\/db13-1087","volume":"63","author":"Gotfredsen C.F.","year":"2014","unstructured":"Gotfredsen C.F.; M\u00f8lck A.M.; Thorup I.; Nyborg N.C.; Salanti Z.; Knudsen L.B.; Larsen M.O.; The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes 2014,63(7),2486-2497","journal-title":"Diabetes"},{"key":"ref=13","first-page":"228","volume":"16","author":"Maguire A.","year":"2007","unstructured":"Maguire A.; Douglas I.; Smeeth L.; Thompson M.;  Pharmacoepidemiol Drug Saf 2007,16,228-228","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"Inzucchi S.E.","year":"2015","unstructured":"Inzucchi S.E.; Bergenstal R.M.; Buse J.B.; Diamant M.; Ferrannini E.; Nauck M.; Peters A.L.; Tsapas A.; Wender R.; Matthews D.R.; Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015,38(1),140-149","journal-title":"Diabetes Care"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"Knudsen L.B.","year":"2019","unstructured":"Knudsen L.B.; Lau J.; The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 2019,10,155","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"Knudsen L.B.","year":"2000","unstructured":"Knudsen L.B.; Nielsen P.F.; Huusfeldt P.O.; Johansen N.L.; Madsen K.; Pedersen F.Z.; Th\u00f8gersen H.; Wilken M.; Agers\u00f8 H.; Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000,43(9),1664-1669","journal-title":"J Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14656566.2018.1552258","volume":"20","author":"Hedrington M.S.","year":"2019","unstructured":"Hedrington M.S.; Davis S.N.; Oral semaglutide for the treatment of type 2 diabetes. Expert Opin Pharmacother 2019,20(2),133-141","journal-title":"Expert Opin Pharmacother"},{"key":"ref=18","unstructured":"FDA. Highlights of prescribing information of ozempic; 2020; pp. 1-51. label ()"},{"key":"ref=19","unstructured":"FDA. Highlights of Prescribing Information of Rybelsus; 2019. label ()"},{"key":"ref=20","first-page":"1","year":"2010","unstructured":"Nordisk Novo A\/S. Victoza (Liraglutide) Full Prescription Information. FDA Packag. Inser. Victoza (liraglutide [rDNA origin] injection ()2010,1-23"},{"key":"ref=21","first-page":"1","volume":"44","year":"2015","unstructured":"European Medicines Agency (EMA). Trulicity dulaglutide EPAR TRULICITY, INN-dulaglutide ()2015,44,1-167","journal-title":"Trulicity dulaglutide EPAR"},{"key":"ref=22","year":"2014","unstructured":"Cent drug eval res appl number 125469Orig1s000 labeling FDA2014","journal-title":"Cent drug eval res appl number 125469Orig1s000 labeling"},{"key":"ref=23","year":"2014","unstructured":"FDA TANZEUM (albiglutide) for injection, for subcutaneous use Initial U.S. Approval: 2014. FDA-Approved Drugs - Drugs@FDA 2014","journal-title":"FDA-Approved Drugs - Drugs@FDA"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"Holst J.J.","year":"2007","unstructured":"Holst J.J.; The physiology of glucagon-like peptide 1. Physiol Rev 2007,87(4),1409-1439","journal-title":"Physiol Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"Baggio L.L.","year":"2007","unstructured":"Baggio L.L.; Drucker D.J.; Biology of incretins: GLP-1 and GIP. Gastroenterology 2007,132(6),2131-2157","journal-title":"Gastroenterology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1113\/jphysiol.2008.164012","volume":"587","author":"Tolhurst G.","year":"2009","unstructured":"Tolhurst G.; Reimann F.; Gribble F.M.; Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009,587(1),27-32","journal-title":"J Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1210\/en.2009-1178","volume":"150","author":"Thurmond D.C.","year":"2009","unstructured":"Thurmond D.C.; Insulin-regulated glucagon-like peptide-1 release from L cells: actin\u2019 out. Endocrinology 2009,150(12),5202-5204","journal-title":"Endocrinology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/1753-0407.12439","volume":"8","author":"Tian L.","year":"2016","unstructured":"Tian L.; Jin T.; The incretin hormone GLP-1 and mechanisms underlying its secretion. J Diabetes 2016,8(6),753-765","journal-title":"J Diabetes"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/diabetes.52.5.1147","volume":"52","author":"From G.P-S.","year":"2003","unstructured":"From G.P-S.; Gribble F.M.; Williams L.; Simpson A.K.; Reimann F.;  Diabetes 2003,52,1147","journal-title":"Diabetes"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"Gorboulev V.","year":"2012","unstructured":"Gorboulev V.; Sch\u00fcrmann A.; Vallon V.; Kipp H.; Jaschke A.; Klessen D.; Friedrich A.; Scherneck S.; Rieg T.; Cunard R.; Veyhl-Wichmann M.; Srinivasan A.; Balen D.; Breljak D.; Rexhepaj R.; Parker H.E.; Gribble F.M.; Reimann F.; Lang F.; Wiese S.; Sabolic I.; Sendtner M.; Koepsell H.; Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012,61(1),187-196","journal-title":"Diabetes"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.2337\/diabetes.51.9.2757","volume":"51","author":"Reimann F.","year":"2002","unstructured":"Reimann F.; Gribble F.M.; Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002,51(9),2757-63","journal-title":"Diabetes"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.cmet.2008.11.002","volume":"8","author":"Reimann F.","year":"2008","unstructured":"Reimann F.; Habib A.M.; Tolhurst G.; Parker H.E.; Rogers G.J.; Gribble F.M.; Glucose sensing in L cells: a primary cell study. Cell Metab 2008,8(6),532-539","journal-title":"Cell Metab"},{"key":"ref=33","first-page":"1","author":"Ahead P. A.","year":"2010","unstructured":"Ahead P. A.;  City 2010,1-31","journal-title":"City"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/bph.12689","volume":"171","author":"Bortolato A.","year":"2014","unstructured":"Bortolato A.; Dor\u00e9 A.S.; Hollenstein K.; Tehan B.G.; Mason J.S.; Marshall F.H.; Structure of Class B GPCRs: new horizons for drug discovery. Br J Pharmacol 2014,171(13),3132-3145","journal-title":"Br J Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/pr.55.1.6","volume":"55","author":"Mayo K.E.","year":"2003","unstructured":"Mayo K.E.; Miller L.J.; Bataille D.; Dalle S.; G\u00f6ke B.; Thorens B.; Drucker D.J.; International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003,55(1),167-194","journal-title":"Pharmacol Rev"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"Doyle M.E.","year":"2007","unstructured":"Doyle M.E.; Egan J.M.; Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007,113(3),546-593","journal-title":"Pharmacol Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","volume":"108","author":"Sharma D.","year":"2018","unstructured":"Sharma D.; Verma S.; Vaidya S.; Kalia K.; Tiwari V.; Recent updates on GLP-1 agonists: Current advancements","journal-title":"Biomed Pharmacother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","volume":"11","author":"Twarog C.","year":"2019","unstructured":"Twarog C.; Fattah S.; Heade J.; Maher S.; Fattal E.; Brayden D.J.; Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C 10). Pharmaceutics 2019,11(2),78","journal-title":"Pharmaceutics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"Buckley S.T.","year":"2018","unstructured":"Buckley S.T.; B\u00e6kdal T.A.; Vegge A.; Maarbjerg S.J.; Pyke C.; Ahnfelt-R\u00f8nne J.; Madsen K.G.; Sch\u00e9ele S.G.; Alanentalo T.; Kirk R.K.; Pedersen B.L.; Skyggebjerg R.B.; Benie A.J.; Strauss H.M.; Wahlund P.O.; Bjerregaard S.; Farkas E.; Fekete C.; S\u00f8ndergaard F.L.; Borregaard J.; Hartoft-Nielsen M.L.; Knudsen L.B.; Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018,10(467),eaar7047","journal-title":"Sci Transl Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ejps.2005.03.003","volume":"25","author":"Hess S.","year":"2005","unstructured":"Hess S.; Rotshild V.; Hoffman A.; Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method. Eur J Pharm Sci 2005,25(2-3),307-312","journal-title":"Eur J Pharm Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jcph.1131","volume":"58","author":"Baekdal T.A.","year":"2018","unstructured":"Baekdal T.A.; Thomsen M.; Kup\u010dov\u00e1 V.; Hansen C.W.; Anderson T.W.; Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol 2018,58(10),1314-1323","journal-title":"J Clin Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"107520","DOI":"10.1016\/j.jdiacomp.2019.107520","volume":"34","author":"Anderson S.L.","year":"2020","unstructured":"Anderson S.L.; Beutel T.R.; Trujillo J.M.; Oral semaglutide in type 2 diabetes. J Diabetes Complications 2020,34(4),107520","journal-title":"J Diabetes Complications"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","volume":"58","author":"B\u00e6kdal T.A.","year":"2019","unstructured":"B\u00e6kdal T.A.; Borregaard J.; Hansen C.W.; Thomsen M.; Anderson T.W.; Effect of oral semaglutide on the pharmacokinetics of Lisinopril, Warfarin, Digoxin, and metformin in healthy subjects. Clin Pharmacokinet 2019,58(9),1193-1203","journal-title":"Clin Pharmacokinet"},{"key":"ref=44","unstructured":"Prod Inf European Medicines Agency (EMA)","journal-title":"Prod Inf"},{"key":"ref=45","year":"2017","unstructured":"Semaglutide Injection. Product Quality Review. Cent DRUG Eval Res Appl NUMBER 209637Orig1s000 Prod Qual Rev FDA209637Orig1s000ChemR.pdf 2017","journal-title":"Cent DRUG Eval Res Appl NUMBER 209637Orig1s000 Prod Qual Rev"},{"key":"ref=46","unstructured":"FDA. Semaglutide: clinical pharmacology and biopharmaceutics review(s); 2016. 209637Orig1s000ClinPharmR.pdf"},{"key":"ref=47","unstructured":"FDA. Highlights of prescribing information 2017. OZEMPIC (semaglutide) injection, for subcutaneous use"},{"key":"ref=48","unstructured":"European medicines agency (EMA). EPAR-Ozempic (Semaglutide). Summary of product characteristics. 1-73. Ozempic, INN-semaglutide"},{"key":"ref=49","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) Japan. New drug approved in FY 2017. 000232769.pdf"},{"key":"ref=50","year":"2018","unstructured":"Ozempic (semaglutide injection) product monograph Inc., N. N. C2018","journal-title":"Ozempic (semaglutide injection) product monograph"},{"key":"ref=51","author":"Canada H.","unstructured":"Canada H.; Rybelsus\u00ae(semaglutide tablets) Product Monograph. Product information"},{"key":"ref=52","unstructured":"Therapeutic good adinistration, department of health, australian government. OZEMPIC 1 mg semaglutide (rys) 1.34 mg\/mL solution for injection pre-filled pen. TGA Search"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"Ahmann A.J.","year":"2018","unstructured":"Ahmann A.J.; Capehorn M.; Charpentier G.; Dotta F.; Henkel E.; Lingvay I.; Holst A.G.; Annett M.P.; Aroda V.R.; Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (sustain 3): A 56-week, open-label, randomized clinical trial. Diabetes Care 2018,41(2),258-266","journal-title":"Diabetes Care"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"Rodbard H.W.","year":"2018","unstructured":"Rodbard H.W.; Lingvay I.; Reed J.; de la Rosa R.; Rose L.; Sugimoto D.; Araki E.; Chu P.L.; Wijayasinghe N.; Norwood P.; Semaglutide added to basal insulin in type 2 diabetes (sustain 5): A randomized, controlled trial. J Clin Endocrinol Metab 2018,103(6),2291-2301","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"Rosenstock J.","year":"2019","unstructured":"Rosenstock J.; Allison D.; Birkenfeld A.L.; Blicher T.M.; Deenadayalan S.; Jacobsen J.B.; Serusclat P.; Violante R.; Watada H.; Davies M.;  JAMA - J Am Med Assoc 2019,321,1466-1480","journal-title":"JAMA - J Am Med Assoc"},{"key":"ref=56","unstructured":"Coronavirus disease 2019 (COVID-19) Situation Report \u2013 88. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports"},{"key":"ref=57","unstructured":"FDA. Center for drug evaluation and research. application number: 213051orig1s000 Clinical Review(S). Review ()"},{"key":"ref=58","unstructured":"EMA. Product information of rybelsus epar product information. Rybelsus, INN-semaglutide ()"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jama.289.1.76","volume":"289","author":"Mokdad A.H.","year":"2003","unstructured":"Mokdad A.H.; Ford E.S.; Bowman B.A.; Dietz W.H.; Vinicor F.; Bales V.S.; Marks J.S.; Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003,289(1),76-79","journal-title":"JAMA"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.nut.2009.07.008","volume":"26","author":"Bradley D.P.","year":"2010","unstructured":"Bradley D.P.; Kulstad R.; Schoeller D.A.; Exenatide and weight loss. Nutrition 2010,26(3),243-249","journal-title":"Nutrition"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","volume":"62","author":"Kanoski S.E.","year":"2012","unstructured":"Kanoski S.E.; Rupprecht L.E.; Fortin S.M.; De Jonghe B.C.; Hayes M.R.; The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012,62(5-6),1916-1927","journal-title":"Neuropharmacology"},{"key":"ref=62","first-page":"672658","volume":"2012","author":"Monami M.","year":"2012","unstructured":"Monami M.; Dicembrini I.; Marchionni N.; Rotella C. M.; Mannucci E.; Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012,2012,672658","journal-title":"Exp Diabetes Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1210\/en.2014-1675","volume":"156","author":"Heppner K.M.","year":"2015","unstructured":"Heppner K.M.; Kirigiti M.; Secher A.; Paulsen S.J.; Buckingham R.; Pyke C.; Knudsen L.B.; Vrang N.; Grove K.L.; Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015,156(1),255-267","journal-title":"Endocrinology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.physbeh.2010.02.029","volume":"100","author":"Hayes M.R.","year":"2010","unstructured":"Hayes M.R.; De Jonghe B.C.; Kanoski S.E.; Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 2010,100(5),503-510","journal-title":"Physiol Behav"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","volume":"310","author":"Kanoski S.E.","year":"2016","unstructured":"Kanoski S.E.; Hayes M.R.; Skibicka K.P.; GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 2016,310(10),R885-R895","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fphys.2018.00900","volume":"9","author":"Bliss E.S.","year":"2018","unstructured":"Bliss E.S.; Whiteside E.; The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front Physiol 2018,9,900","journal-title":"Front Physiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"Blundell J.","year":"2017","unstructured":"Blundell J.; Finlayson G.; Axelsen M.; Flint A.; Gibbons C.; Kvist T.; Hjerpsted J.B.; Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017,19(9),1242-1251","journal-title":"Diabetes Obes Metab"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s40265-014-0298-1","volume":"74","author":"Scott L.J.","year":"2014","unstructured":"Scott L.J.; Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014,74(15),1769-1784","journal-title":"Drugs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"Frampton J.E.","year":"2018","unstructured":"Frampton J.E.; Empagliflozin: A review in type 2 diabetes. Drugs 2018,78(10),1037-1048","journal-title":"Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/jc.2017-01838","volume":"103","author":"Al Jobori H.","year":"2018","unstructured":"Al Jobori H.; Daniele G.; Adams J.; Cersosimo E.; Solis-Herrera C.; Triplitt C.; DeFronzo R.A.; Abdul-Ghani M.; Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus. J Clin Endocrinol Metab 2018,103(4),1402-1407","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"Monami M.","year":"2014","unstructured":"Monami M.; Nardini C.; Mannucci E.; Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014,16(5),457-466","journal-title":"Diabetes Obes Metab"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1172\/JCI76184","volume":"124","author":"Merovci A.","year":"2014","unstructured":"Merovci A.; Solis-Herrera C.; Daniele G.; Eldor R.; Fiorentino T.V.; Tripathy D.; Xiong J.; Perez Z.; Norton L.; Abdul-Ghani M.A.; DeFronzo R.A.;  J Clin Invest 2014,124,2287","journal-title":"J Clin Invest"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00386","volume":"6","author":"R\u00f6hrborn D.","year":"2015","unstructured":"R\u00f6hrborn D.; Wronkowitz N.; Eckel J.;  Front Immunol 2015,6,1-20","journal-title":"Front Immunol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4103\/2230-8210.111625","volume":"17","author":"Gupta V.","year":"2013","unstructured":"Gupta V.; Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab 2013,17(3),413-421","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"104","DOI":"10.18773\/austprescr.2008.059","volume":"31","author":"Reutens A.T.","year":"2008","unstructured":"Reutens A.T.; Shaw J.E.; Incretin mimetics and enhancers: clinical applications. Aust Prescr 2008,31,104-108","journal-title":"Aust Prescr"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1089\/dia.2011.0050","volume":"13","author":"DeYoung M.B.","year":"2011","unstructured":"DeYoung M.B.; MacConell L.; Sarin V.; Trautmann M.; Herbert P.; Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011,13(11),1145-1154","journal-title":"Diabetes Technol Ther"},{"key":"ref=77","author":"Atkinson M.A.","year":"2016","unstructured":"Atkinson M.A.;  Chapter 32 \u2013 type 1 diabetes mellitus Thirteenth2016","journal-title":"Chapter 32 \u2013 type 1 diabetes mellitus"},{"key":"ref=78","volume":"6","year":"2015","unstructured":"Pro.medicin.dk Lantus\u00ae. ProMedicinDk 2015,6","journal-title":"ProMedicinDk"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/VHRM.S10952","volume":"6","author":"Foley J.E.","year":"2010","unstructured":"Foley J.E.; Jordan J.; Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 2010,6,541-548","journal-title":"Vasc Health Risk Manag"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"Pereira M.J.","year":"2019","unstructured":"Pereira M.J.; Eriksson J.W.; Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019,79(3),219-230","journal-title":"Drugs"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1080\/00325481.2017.1342509","volume":"129","author":"Busch R.S.","year":"2017","unstructured":"Busch R.S.; Kane M.P.; Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgrad Med 2017,129(7),686-697","journal-title":"Postgrad Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"Ferrannini E.","year":"2016","unstructured":"Ferrannini E.; Baldi S.; Frascerra S.; Astiarraga B.; Heise T.; Bizzotto R.; Mari A.; Pieber T.R.; Muscelli E.; Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016,65(5),1190-1195","journal-title":"Diabetes"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC201903050","volume":"170","author":"Tsai A.G.","year":"2019","unstructured":"Tsai A.G.; Bessesen D.H.; Obesity. Ann Intern Med 2019,170(5),ITC33-ITC48","journal-title":"Ann Intern Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"Zaccardi F.","year":"2016","unstructured":"Zaccardi F.; Webb D.R.; Htike Z.Z.; Youssef D.; Khunti K.; Davies M.J.; Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016,18(8),783-794","journal-title":"Diabetes Obes Metab"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"Rodbard H.W.","year":"2019","unstructured":"Rodbard H.W.; Rosenstock J.; Canani L.H.; Deerochanawong C.; Gumprecht J.; Lindberg S.\u00d8.; Lingvay I.; S\u00f8ndergaard A.L.; Treppendahl M.B.; Montanya E.; Oral Semaglutide versus Empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The pioneer 2 trial. Diabetes Care 2019,42(12),2272-2281","journal-title":"Diabetes Care"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"Pratley R.","year":"2019","unstructured":"Pratley R.; Amod A.; Hoff S.T.; Kadowaki T.; Lingvay I.; Nauck M.; Pedersen K.B.; Saugstrup T.; Meier J.J.; Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019,394(10192),39-50","journal-title":"Lancet"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"Aroda V.R.","year":"2019","unstructured":"Aroda V.R.; Rosenstock J.; Terauchi Y.; Altuntas Y.; Lalic N.M.; Morales Villegas E.C.; Jeppesen O.K.; Christiansen E.; Hertz C.L.; Haluz\u00edk M.; PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019,42(9),1724-1732","journal-title":"Diabetes Care"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"Sorli C.","year":"2017","unstructured":"Sorli C.; Harashima S.ichi.; Tsoukas G. M.; Unger J.; Karsb\u00f8l J. D.; Hansen T.; Bain S. C.; Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet diabetes endocrinol 2017,5,251-260","journal-title":"Lancet diabetes endocrinol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"Mosenzon O.","year":"2019","unstructured":"Mosenzon O.; Blicher T.M.; Rosenlund S.; Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019,7,515-527","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"Einarson T.R.","year":"2018","unstructured":"Einarson T.R.; Acs A.; Ludwig C.; Panton U.H.; Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes. Cardiovasc Diabetol 2018,17,1-19","journal-title":"Cardiovasc Diabetol"},{"key":"ref=91","unstructured":"European Medicines Agency (EMA) EPAR. Trulicity (Dulaglutide) public assessment report. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trulicity"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Bain S.C.; Consoli A.; Eliaschewitz F.G.; J\u00f3dar E.; Leiter L.A.; Lingvay I.; Rosenstock J.; Seufert J.; Warren M.L.; Woo V.; Hansen O.; Holst A.G.; Pettersson J.; Vilsb\u00f8ll T.; Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016,375(19),1834-1844","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.2147\/DMSO.S229802","volume":"12","author":"Pearson S.","year":"2019","unstructured":"Pearson S.; Kietsiriroje N.; Ajjan R.A.; Diabetes. Diabetes Metab Syndr Obes 2019,12,2515-2529","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"Husain M.","year":"2019","unstructured":"Husain M.; Birkenfeld A.L.; Donsmark M.; Dungan K.; Eliaschewitz F.G.; Franco D.R.; Jeppesen O.K.; Lingvay I.; Mosenzon O.; Pedersen S.D.; Tack C.J.; Thomsen M.; Vilsb\u00f8ll T.; Warren M.L.; Bain S.C.; Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019,381(9),841-851","journal-title":"N Engl J Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/obr.12839","volume":"20","author":"Christou G.A.","year":"2019","unstructured":"Christou G.A.; Katsiki N.; Blundell J.; Fruhbeck G.; Kiortsis D.N.; Semaglutide as a promising antiobesity drug. Obes Rev 2019,20(6),805-815","journal-title":"Obes Rev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0140-6736(18)33195-7","volume":"394","author":"Xiao Y.","year":"2019","unstructured":"Xiao Y.; Sun L.; Semaglutide in weight management. Lancet 2019,394(10205),1226","journal-title":"Lancet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/bmj.k1767","author":"Carreras-Torres R.","year":"2018","unstructured":"Carreras-Torres R.; Johansson M.; Haycock P.C.; Relton C.L.; Davey Smith G.; Brennan P.; Martin R.M.; Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. BMJ 2018,361","journal-title":"BMJ"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"435","DOI":"10.7326\/0003-4819-153-7-201010050-00006","volume":"153","author":"Nedeltcheva A.V.","year":"2010","unstructured":"Nedeltcheva A.V.; Kilkus J.M.; Imperial J.; Schoeller D.A.; Penev P.D.; Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med 2010,153(7),435-441","journal-title":"Ann Intern Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0140-6736(19)31904-X","volume":"394","author":"Wilding J.P.H.","year":"2019","unstructured":"Wilding J.P.H.; Semaglutide in weight management - author\u2019s reply. Lancet 2019,394(10205),1226-1227","journal-title":"Lancet"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"O\u2019Neil P.M.","year":"2018","unstructured":"O\u2019Neil P.M.; Birkenfeld A.L.; McGowan B.; Mosenzon O.; Pedersen S.D.; Wharton S.; Carson C.G.; Jepsen C.H.; Kabisch M.; Wilding J.P.H.; Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018,392(10148),637-649","journal-title":"Lancet"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"Kushner R.F.","year":"2020","unstructured":"Kushner R.F.; Calanna S.; Davies M.; Dicker D.; Garvey W.T.; Goldman B.; Lingvay I.; Thomsen M.; Wadden T.A.; Wharton S.; Wilding J.P.H.; Rubino D.; Semaglutide 2.4 mg for the treatment of obesity: key elements of the step trials 1 to 5. Obesity (Silver Spring) 2020,28(6),1050-1061","journal-title":"Obesity (Silver Spring)"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","volume":"136","author":"H\u00f6lscher C.","year":"2018","unstructured":"H\u00f6lscher C.; Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology 2018,136(Pt B),251-259","journal-title":"Neuropharmacology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-2006-9102","volume":"9","author":"Lester-Coll N.","year":"2006","unstructured":"Lester-Coll N.; Rivera E.J.; Soscia S.J.; Doiron K.; Wands J.R.; de la Monte S.M.; Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer\u2019s disease. J Alzheimers Dis 2006,9(1),13-33","journal-title":"J Alzheimers Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"Moloney A.M.","year":"2010","unstructured":"Moloney A.M.; Griffin R.J.; Timmons S.; O\u2019Connor R.; Ravid R.; O\u2019Neill C.; Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer\u2019s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010,31(2),224-243","journal-title":"Neurobiol Aging"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"Talbot K.","year":"2012","unstructured":"Talbot K.; Wang H.Y.; Kazi H.; Han L.Y.; Bakshi K.P.; Stucky A.; Fuino R.L.; Kawaguchi K.R.; Samoyedny A.J.; Wilson R.S.; Arvanitakis Z.; Schneider J.A.; Wolf B.A.; Bennett D.A.; Trojanowski J.Q.; Arnold S.E.; Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012,122(4),1316-1338","journal-title":"J Clin Invest"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-2005-7107","volume":"7","author":"Steen E.","year":"2005","unstructured":"Steen E.; Terry B.M.; Rivera E.J.; Cannon J.L.; Neely T.R.; Tavares R.; Xu X.J.; Wands J.R.; de la Monte S.M.; Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease-is this type 3 diabetes? J Alzheimers Dis 2005,7(1),63-80","journal-title":"J Alzheimers Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","volume":"231","author":"Morris J.K.","year":"2011","unstructured":"Morris J.K.; Bomhoff G.L.; Gorres B.K.; Davis V.A.; Kim J.; Lee P.P.; Brooks W.M.; Gerhardt G.A.; Geiger P.C.; Stanford J.A.; Insulin resistance impairs nigrostriatal dopamine function. Exp Neurol 2011,231(1),171-180","journal-title":"Exp Neurol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.brainres.2008.08.089","volume":"1240","author":"Morris J.K.","year":"2008","unstructured":"Morris J.K.; Zhang H.; Gupte A.A.; Bomhoff G.L.; Stanford J.A.; Geiger P.C.; Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson\u2019s disease. Brain Res 2008,1240,185-195","journal-title":"Brain Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/ene.12137","volume":"21","author":"Pellecchia M.T.","year":"2014","unstructured":"Pellecchia M.T.; Santangelo G.; Picillo M.; Pivonello R.; Longo K.; Pivonello C.; Vitale C.; Amboni M.; De Rosa A.; Moccia M.; Erro R.; De Michele G.; Santoro L.; Colao A.; Barone P.; Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-na\u00efve Parkinson\u2019s disease. Eur J Neurol 2014,21(5),802-807","journal-title":"Eur J Neurol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.parkreldis.2013.11.005","volume":"20","author":"Numao A.","year":"2014","unstructured":"Numao A.; Suzuki K.; Miyamoto M.; Miyamoto T.; Hirata K.; Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson\u2019s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2014,20(2),212-216","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/brain\/aws009","volume":"136","author":"Aviles-Olmos I.","year":"2013","unstructured":"Aviles-Olmos I.; Limousin P.; Lees A.; Foltynie T.; Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection. Brain 2013,136(Pt 2),374-384","journal-title":"Brain"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2337\/dbi18-0045","volume":"68","author":"Daniels D.","year":"2019","unstructured":"Daniels D.; Mietlicki-Baase E.G.; Glucagon-like peptide 1 in the brain: where is it coming from, where is it going? Diabetes 2019,68(1),15-17","journal-title":"Diabetes"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"Zhang L.","year":"2019","unstructured":"Zhang L.; Zhang L.; Li L.; H\u00f6lscher C.; Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis 2019,9(1),157-171","journal-title":"J Parkinsons Dis"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"Femminella G.D.","year":"2019","unstructured":"Femminella G.D.; Frangou E.; Love S.B.; Busza G.; Holmes C.; Ritchie C.; Lawrence R.; McFarlane B.; Tadros G.; Ridha B.H.; Bannister C.; Walker Z.; Archer H.; Coulthard E.; Underwood B.R.; Prasanna A.; Koranteng P.; Karim S.; Junaid K.; McGuinness B.; Nilforooshan R.; Macharouthu A.; Donaldson A.; Thacker S.; Russell G.; Malik N.; Mate V.; Knight L.; Kshemendran S.; Harrison J.; Brooks D.J.; Passmore A.P.; Ballard C.; Edison P.; The bowel preparation for magnetic resonance enterography in patients with Crohn's disease: study protocol for a randomized controlled trial. Trials 2019,20,1-10","journal-title":"Trials"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"Drucker D.J.","year":"2018","unstructured":"Drucker D.J.; Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018,27(4),740-756","journal-title":"Cell Metab"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clinre.2019.01.009","volume":"43","author":"Barbato G.M.","year":"2019","unstructured":"Barbato G.M.; Cadamuro M.; Fabris L.; Incretin-based treatment in type 2 diabetes mellitus and risk of cholangiocarcinoma: Is it only adverse drug effect? Clin Res Hepatol Gastroenterol 2019,43(3),232-235","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"Drucker D.J.","year":"2006","unstructured":"Drucker D.J.; The biology of incretin hormones. Cell Metab 2006,3(3),153-165","journal-title":"Cell Metab"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"Ussher J.R.","year":"2012","unstructured":"Ussher J.R.; Drucker D.J.; Cardiovascular biology of the incretin system. Endocr Rev 2012,33(2),187-215","journal-title":"Endocr Rev"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"Knudsen L.B.","year":"2010","unstructured":"Knudsen L.B.; Madsen L.W.; Andersen S.; Almholt K.; De Boer A.S.; Drucker D.J.; Gotfredsen C.; Egerod F.L.; Hegelund A.C.; Jacobsen H.; Jacobsen S.D.; Moses A.C.; M\u00f8lck A.M.; Nielsen H.S.; Nowak J.; Solberg H.; Thi T.D.L.; Zdravkovic M.; Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010,151,1473-1486","journal-title":"Endocrinology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1534365","DOI":"10.1155\/2019\/1534365","volume":"2019","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Zhang X.; Chai S.; Zhao X.; Ji L.; Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: A meta-analysis. J Diabetes Res 2019,2019,1534365","journal-title":"J Diabetes Res"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450122666210901125420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/196035\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450122666210901125420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:04:58Z","timestamp":1660716298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/196035\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450122666210901125420","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}